Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
GILD Price Action
Last 7 days
0.5%
Last 30 days
-7.4%
Last 90 days
6.6%
Trailing 12 Months
58.7%
GILD RSI Chart
GILD Valuation
GILD Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
GILD Fundamentals
GILD Revenue
GILD Earnings
GILD Profitability
GILD Investor Care
GILD Alerts
Revenue & Growth
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2024 | 27.4B | 27.8B | 28.3B | 28.8B |
| 2023 | 27.0B | 27.4B | 27.4B | 27.1B |
| 2022 | 27.5B | 27.5B | 27.1B | 27.3B |
| 2021 | 25.6B | 26.6B | 27.5B | 27.3B |
| 2020 | 22.7B | 22.2B | 23.1B | 24.7B |
| 2019 | 22.3B | 22.4B | 22.4B | 22.4B |
| 2018 | 24.7B | 23.2B | 22.3B | 22.1B |
| 2017 | 29.1B | 28.5B | 27.5B | 26.1B |
| 2016 | 32.8B | 32.4B | 31.6B | 30.4B |
| 2015 | 27.5B | 29.2B | 31.4B | 32.6B |
| 2014 | 13.7B | 17.4B | 20.7B | 24.9B |
| 2013 | 10.0B | 10.3B | 10.7B | 11.2B |
| 2012 | 8.7B | 9.0B | 9.3B | 9.7B |
| 2011 | 7.8B | 8.0B | 8.2B | 8.4B |
| 2010 | 7.6B | 7.8B | 8.0B | 7.9B |
| 2009 | 5.6B | 6.0B | 6.4B | 7.0B |
| 2008 | 0 | 4.6B | 5.0B | 5.3B |
| 2007 | 0 | 0 | 0 | 4.2B |
Get all data in R, Python etc through our Historical Stock Data APIs
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc. and Tentarix Biotherapeutics Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
| CEO | Mr. Daniel P. O'Day |
|---|---|
| WEBSITE | gilead.com |
| SECTOR | Healthcare |
| INDUSTRY | Drug Manufacturers General |
| EMPLOYEES | 17000 |
